NCT05407818View on ClinicalTrials.gov

A Study of JNJ-63733657 in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

August 2, 2022

Study Completion Date

November 7, 2022

Conditions

Healthy

Interventions

DRUG

JNJ-63733657

JNJ-63733657 will be administered as an IV infusion.

Trial Locations (1)

100089

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY